Accordingly, these diuretic actions are likely to explain the primary mechanisms underlying accumulated evidence on SGLT2 inhibitor-induced risk reduction of heart failure (HF) and renal events in a broad range of subjects, irrespective of diabetes and HF clinical situations [6–8]. Here, SLC5A2 is linked to diabetes mellitus.